Liraglutide is a well-known prescription medication, but it is not commercially available or approved in a single 10mg dose. The maximum approved daily doses for Liraglutide are significantly lower.

The information below details Liraglutide’s official uses and maximum approved doses under its common brand names.

Liraglutide Overview and Approved Dosing

Liraglutide is a prescription medication classified as a GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist). It is administered as a once-daily subcutaneous injection (under the skin) using a pre-filled pen device.

It is marketed under two different brand names, each with a different maximum approved daily dose:

1. Saxenda (Liraglutide for Weight Management)

• Maximum Approved Daily Dose: 3.0 mg (milligrams)
• Purpose: Chronic weight management in adults and some adolescents who are obese or overweight with at least one weight-related condition.
• Dosing Schedule: Treatment is initiated at a low dose (0.6 mg once daily) and is gradually increased over several weeks (titration) to the maintenance dose of 3.0 mg/day to minimize gastrointestinal side effects (like nausea and vomiting).

2. Victoza (Liraglutide for Type 2 Diabetes)

• Maximum Approved Daily Dose: 1.8 mg (milligrams)
• Purpose: To improve blood sugar control in adults and some children with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
• Dosing Schedule: Treatment is initiated at 0.6 mg once daily for one week, then increased to 1.2 mg/day, and may be further increased to the maximum of 1.8 mg/day if needed for better glycemic control.

Why Liraglutide 10mg is Not Standard

• Maximum Dose Limit: The highest FDA-approved dose for Liraglutide is 3.0 mg per day (for weight management). A 10mg single dose is more than three times this maximum.
• Safety and Efficacy: Doses significantly exceeding the approved maximum are not studied or approved due to unknown risks and increased likelihood of severe side effects, particularly intense gastrointestinal issues (nausea, vomiting, diarrhea) and potentially more serious events like pancreatitis.
• Vial Concentration: While Liraglutide pens contain a total volume of medication (e.g., 18 mg in a 3 mL pen), the daily dose delivered is strictly controlled to be 3.0 mg or less. The mention of “10mg” may refer to bulk powder (similar to the peptide context) or a misinterpretation of a product’s total content, but it is not a standard or safe daily dose.

Important Medical Warning

Never self-administer or use a dose of Liraglutide (or any medication) that significantly exceeds the maximum dosage prescribed or approved by regulatory bodies. Dosing should only be determined and monitored by a qualified healthcare professional who can assess your medical history and individual needs.